FTX-101 / Find Therapeutics - LARVOL DELTA

SAD and MAD Study of FTX-101 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=49 | Terminated | Sponsor: Find Therapeutics | N=80 ➔ 49 | Recruiting ➔ Terminated; Study's goals have been achieved based on a preliminary analysis of available pharmacokinetic and safety data, which demonstrate that sufficient information has been obtained.

Enrollment change • Trial termination

Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology. (PubMed, Biomed Pharmacother) - "FTX-101 enhanced the recruitment of oligodendrocytes and promoted myelination, addressing critical medical needs in demyelinating conditions. Specificity, solubility in water, and enduring stability render FTX-101 a highly promising candidate for a first-in-class therapeutic agent."

Journal • CNS Disorders • Solid Tumor • NRP1 • PLXNA1 • SEMA3A

FTX-101 Enters BBB, Restores Myelin, and Protects the Visual Function During Neuroinflammation (ACTRIMS Forum 2025) - "FTX-101 crosses the BBB, and during neuroinflammation, activates differentiation and migration of OPCs and OLs resulting in improved clinical scores, increased remyelination and neuroprotection. Importantly, synergistic effects were seen with fingolimod suggesting that combining FTX-101 with highly-effective DMTs may have an enhanced benefit for pwMS."

CNS Disorders • Immune Modulation • Inflammation • Multiple Sclerosis • Solid Tumor • NRP1 • PLP1 • SEMA3A